{"id":"NCT01854775","sponsor":"Gilead Sciences","briefTitle":"Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children","officialTitle":"A Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2013-05-06","primaryCompletion":"2020-05-11","completion":"2025-06-18","firstPosted":"2013-05-16","resultsPosted":"2021-05-24","lastUpdate":"2025-07-23"},"enrollment":129,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Acquired Immune Deficiency Syndrome (AIDS)","HIV Infections"],"interventions":[{"type":"DRUG","name":"E/C/F/TAF","otherNames":["Genvoya®"]},{"type":"DRUG","name":"E/C/F/TAF (Low Dose)","otherNames":[]}],"arms":[{"label":"Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg","type":"EXPERIMENTAL"},{"label":"Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg","type":"EXPERIMENTAL"},{"label":"Cohort 3: Age ≥2 Years and Weight ≥ 14 to <25 kg","type":"EXPERIMENTAL"}],"summary":"The primary objectives of Cohort 1 are to evaluate the steady state pharmacokinetics (PK) for elvitegravir (EVG) and tenofovir alafenamide (TAF) and confirm the dose of the elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) STR (Part A) and to evaluate the safety and tolerability of E/C/F/TAF STR through Week 24 (Part B) in human immunodeficiency virus - 1 (HIV-1) infected, antiretroviral (ARV) treatment-naive adolescents.\n\nThe primary objectives of Cohort 2 are to evaluate the PK of EVG and TAF in virologically suppressed HIV-1 infected children 6 to \\< 12 years of age weighing ≥ 25 kg administered E/C/F/TAF STR (Part A) and to evaluate the safety and tolerability of E/C/F/TAF STR through Week 24 in virologically suppressed HIV-1 infected children 6 to \\< 12 years of age weighing ≥ 25 kg (Part B).\n\nThe primary objectives of Cohort 3 are to evaluate the PK of EVG and TAF and confirm the dose of the STR, and to evaluate the safety and tolerability of E/C/F/TAF low dose (LD) STR in virologically suppressed HIV-1 infected children ≥ 2 years of age and weighing ≥ 14 to \\< 25 kg.","primaryOutcome":{"measure":"Pharmacokinetic (PK) Parameter: AUCtau of Elvitegravir (EVG) (Cohort 1)","timeFrame":"0 (pre-dose, ≤ 30 minutes prior to dosing), 5 minutes, 0.25, 0.5, 1, 1.5, 2, 4, 5, 8 and 24 hours post-dose at Week 4","effectByArm":[{"arm":"Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg","deltaMin":23840.1,"sd":6076.15}],"pValues":[]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":4},"locations":{"siteCount":16,"countries":["United States","South Africa","Thailand","Uganda","Zimbabwe"]},"refs":{"pmids":["30169223","27765666","39888251"],"seeAlso":["https://www.gileadclinicaltrials.com/study/?id=GS-US-292-0106"]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":50},"commonTop":["Upper respiratory tract infection","Respiratory tract infection","Vomiting","Diarrhoea","Abdominal pain"]}}